Perseverance in the Wake of Adversity
The year 2020 was a transformative one for the life sciences industry. 2021 has been no different. Over the past two years, the life sciences industry has found itself at the forefront of the public eye as the world turned to every corner of the industry to map out solutions to the global pandemic. At Goodwin, we are incredibly proud to serve as legal counsel and trusted business advisors to our extraordinary clients across the life sciences ecosystem.
We sincerely look forward to what this year will bring as we continue our work to help fuel our inspiring clients’ next innovations.
North Asia: BeiGene’s Global Strategic Oncology Collaboration with Amgen
Presented with “Best Client-Law Firm Team of 2021” award for our work with Moderna
Global Market Recognition
Closing Notable Deals
We are proud to have counseled our clients on some of the most notable deals of 2021. Click on the logos below to learn more about some of our highlights.
Learn More
Explore additional information about our practice, including our full list of press releases, webinars, awards and rankings, thought leadership and upcoming events:
This informational piece, which may be considered advertising under the ethical rules of certain jurisdictions, is provided on the understanding that it does not constitute the rendering of legal advice or other professional advice by Goodwin Procter or its lawyers. Prior results do not guarantee a similar outcome. Goodwin Procter is an international legal practice carried on by Goodwin Procter LLP and its affiliated entities. For further information about our offices and the regulatory regimes that apply to them, please refer to
© 2022 Goodwin Procter. All rights reserved
Life Sciences Practice Page
Life Sciences Perspectives Blog
Goodwin + KPMG @ JPMorgan Symposium
Goodwin’s fully-integrated Life Sciences practice is designed to help clients navigate the rapidly evolving demands by providing a unique “one-stop-shop” service, allowing us to seamlessly advise through all stages of the corporate lifecycle while guiding our clients’ strategic and business goals.
We are proud to have a dedicated team of life sciences lawyers located in the major innovation hubs across the United States, Europe and Asia, giving our team the unique ability to advise clients when and where our services are needed.
Women’s Health and Wellness
Formalized the following new practices:
To grow with our clients, we:
Expanding Our Legal Services
50+ Collaboration Transactions for Over $9.3 Billion
25+ Follow-On Offerings for Over $4.1 Billion*
* Representation of both issuers and underwriters
30+ M&A Transactions for Over $17.4 Billion
170+ Financing (VC) Transactions for Over $14.5 Billion
Achieving New Milestones
30+ IPO Transactions for Over $4.4 Billion*
MedTech
FDA Litigation
Antitrust Services for Life Sciences
M+A Deal of the Year Finalist (2020)
Served as counsel to Cerevel Therapeutics in its $445 million business combination with Arya Sciences Acquisition Corp II and subsequent $350 million initial public offering.
Served as counsel to EQRx in its
$500 million Series B financing and subsequent $1.8 billion business combination with CM Life Sciences III, Inc.
Served as counsel to BridgeBio Pharma in its collaboration with Helsinn Group to develop and commercialize an inhibitor designed to target GPX4 as a new therapy for patients with difficult-to-treat tumors, building off of its $2.45 billion global license and collaboration deals.
Served as counsel to Trillium Therapeutics in its $2.26 billion acquisition by Pfizer, in which Trillium became a wholly-owned subsidiary of Pfizer.
Served as counsel to Arvinas in its collaboration with Pfizer to develop and commercialize PROTAC® protein degrader ARV-471 for an upfront payment of $650 million and up to $400 million in approval milestones, as well as up to $1 billion in commercial milestones.
Served as counsel to UK-based Centessa Pharmaceuticals in its $250 million financing round in tandem with its acquisition of 10 private biotech companies and subsequent $379.5 million initial public offering.
Served as counsel to Blueprint Medicines in its acquisition of Lengo Therapeutics for $250 million upfront and up to a total of $465 million for an oral precision therapy used to treat non-small cell lung cancer.
Served as counsel to longtime client Flagship Pioneering on a first-of-its-kind strategic partnership with the Cystic Fibrosis Foundation and Pioneering Medicines, with
$110 million in committed funding.
goodwinlaw.com/Legal-Notices
Click on the photos to learn more.
“Growing up as a competitive figure skater in the Bay Area, Kristi Yamaguchi was my idol!...I’ve followed her exemplary work ethic my whole life, even after I retired from the sport.”
Judy Lao, Manager,
Client Development
Expanded our life sciences market presence in Europe, including the launch of our practice in France.
Named a leader in patent law across a range of specialties and geographies
Ranked seven-time winner of “Biotechnology Law Firm of the Year” and recognized for FDA Law
Ranked Band 1 in the Nationwide: Life Sciences category
Recognized in the
UK-Wide Life
Sciences category
Recognized as a U.S. Lifecycle firm for the 10th consecutive year
Added more than 220 lawyers across the United States, Europe and Asia.
Launched The Patent Savvy Executive Knowledge Center.
* Representation of both issuers and underwriters
50+ Collaboration Transactions for Over $9.3 Billion
25+ Follow-On Offerings for Over $4.1 Billion*
30+ IPO Transactions for Over $4.4 Billion*
30+ M&A Transactions for Over $17.4 Billion
170+ Financing (VC) Transactions for Over $14.5 Billion
Achieving New Milestones
To grow with our clients, we:
Formalized the following new practices:
M+A Deal of the Year Finalist (2020)
North Asia: BeiGene’s Global Strategic Oncology Collaboration with Amgen
Presented with “Best Client-Law Firm Team of 2021” award for our work with Moderna
Global Market Recognition
We are proud to have counseled our clients on some of the most notable deals of 2021. Click on the logos below to learn more about some of our highlights.
Closing Notable Deals
Served as counsel to BridgeBio Pharma in its collaboration with Helsinn Group to develop and commercialize an inhibitor designed to target GPX4 as a new therapy for patients with difficult-to-treat tumors, building off of its $2.45 billion global license and collaboration deals.
Served as counsel to EQRx in its $500 million Series B financing and subsequent $1.8 billion business combination with CM Life Sciences III, Inc.
Served as counsel to Trillium Therapeutics in its $2.26 billion acquisition by Pfizer, in which Trillium became a wholly-owned subsidiary of Pfizer.
Served as counsel to Arvinas in its collaboration with Pfizer to develop and commercialize PROTAC® protein degrader ARV-471 for an upfront payment of $650 million and up to $400 million in approval milestones, as well as up to $1 billion in commercial milestones.
Served as counsel to Blueprint Medicines in its acquisition of Lengo Therapeutics for $250 million upfront and up to a total of $465 million for an oral precision therapy used to treat
non-small cell lung cancer.
Served as counsel to longtime client Flagship Pioneering on a first-of-its-kind strategic partnership with the Cystic Fibrosis Foundation and Pioneering Medicines, with
$110 million in committed funding.
Served as counsel to Cerevel Therapeutics in its $445 million business combination with Arya Sciences Acquisition Corp II and subsequent $350 million initial public offering.
Served as counsel to UK-based Centessa Pharmaceuticals in its $250 million financing round in tandem with its acquisition of 10 private biotech companies and subsequent $379.5 million initial public offering.
This informational piece, which may be considered advertising under the ethical rules of certain jurisdictions, is provided on the understanding that it does not constitute the rendering of legal advice or other professional advice by Goodwin Procter or its lawyers. Prior results do not guarantee a similar outcome. Goodwin Procter is an international legal practice carried on by Goodwin Procter LLP and its affiliated entities. For further information about our offices and the regulatory regimes that apply to them, please refer to goodwinlaw.com/legal-notices. © 2022 Goodwin Procter.
All rights reserved
Goodwin + KPMG @ JPMorgan Symposium
Life Sciences Perspectives Blog
Life Sciences Practice Page
Explore additional information about our practice, including our full list of press releases, webinars, awards and rankings, thought leadership and upcoming events:
Goodwin’s fully-integrated Life Sciences practice is designed to help clients navigate the rapidly evolving demands by providing a unique “one-stop-shop” service, allowing us to seamlessly advise through all stages of the corporate lifecycle while guiding our clients’ strategic and business goals.
We are proud to have a dedicated team of life sciences lawyers located in the major innovation hubs across the United States, Europe and Asia, giving our team the unique ability to advise clients when and where our services are needed.
Learn More
Expanding Our Legal Services
The year 2020 was a transformative one for the life sciences industry. 2021 has been no different. Over the past two years, the life sciences industry has found itself at the forefront of the public eye as the world turned to every corner of the industry to map out solutions to the global pandemic. At Goodwin, we are incredibly proud to serve as legal counsel and trusted business advisors to our extraordinary clients across the life sciences ecosystem.
We sincerely look forward to what this year will bring as we continue our work to help fuel our inspiring clients’ next innovations.
Perseverance in the Wake of Adversity
Antitrust Services for Life Sciences
FDA Litigation
MedTech
Women’s Health and Wellness
Served as counsel to UK-based Kymab in its acquisition by Sanofi for approximately $1.1 billion
and up to $350 million upon achievement of certain milestones.
Served as counsel to Intellia Therapeutics in its $690 million underwritten public offering on the heels of releasing the first-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans.
Served as counsel to China-based Zai Lab Limited in its broad strategic collaboration and license agreement with MacroGenics to develop and commercialize preclinical bispecific antibodies in oncology, involving up to four immuno-oncology molecules.
Served as counsel to the underwriters of Genenta Science S.p.A.’s upsized initial public offering, which made history as the first Italian biotech to be listed on the Nasdaq.
Ranked the number one law firm for Global M&A Deals in 2021
Honored for our Life Sciences practice in the Healthcare, Pharma & Life Sciences categories
Recognized in the
Life Sciences and Healthcare categories
Served as counsel to UK-based Kymab in its acquisition by Sanofi for approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
Served as counsel to Intellia Therapeutics in its $690 million underwritten public offering on the heels of releasing the first-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans.
Served as counsel to China-based Zai Lab Limited in its broad strategic collaboration and license agreement with MacroGenics to develop and commercialize preclinical bispecific antibodies in oncology, involving up to four immuno-oncology molecules.
Served as counsel to the underwriters of Genenta Science S.p.A.’s upsized initial public offering, which made history as the first Italian biotech to be listed on the Nasdaq.
Recognized as a U.S. Lifecycle firm for the 10th consecutive year
Named a leader in patent law across a range of specialties and geographies
Presented with “Best Client-Law Firm Team of 2021” award for our work with Moderna
Recognized in the UK-Wide Life Sciences category
Ranked Band 1 in the Nationwide: Life Sciences category
Ranked seven-time winner of “Biotechnology Law Firm of the Year” and recognized for
FDA Law